Global Information
회사소개 | 문의 | 비교리스트

홍역(마진) : 파이프라인 리뷰

Measles - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 251554
페이지 정보 영문 43 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


홍역(마진) : 파이프라인 리뷰 Measles - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 43 Pages

홍역(마진)은 바이러스에 기인한 감염성이 높은 질병입니다. 바이러스는 감염자의 코 점액과 목에 서식합니다. 감염은 신체적 접촉, 기침, 재채기에 의해 확산됩니다. 홍역의 가장 일반적인 증상은 고열, 안질(결막염)이며, 처음에 콧물이 나오고 작은 흰 점이 입안에 1일째 이후에 나타나는 경우를 많이 볼 수 있습니다. 그 후에 설사나 구토도 일어납니다.

홍역(마진) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 정리하여 전해드립니다.

서론

  • 조사 범위

홍역 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 치료제
  • 대학/기관별 치료제
  • 기업에서 개발중인 제품
  • 대학/기관에서 연구중인 제품

홍역 : 치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

홍역 치료제 개발 참여 기업

  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • Daiichi-Sankyo
  • GlaxoSmithKline Plc
  • Prometheon Pharma LLC
  • Sinovac Biotech Ltd
  • VBI Vaccines Inc
  • Vical Inc
  • Zydus Cadila Healthcare Ltd

약제 프로파일

홍역 : 휴지 상태인 프로젝트

홍역 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.06.21

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Measles, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Measles - Pipeline by Biological E Ltd, H1 2020
  • Measles - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Measles - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Measles - Pipeline by Enesi Pharma Ltd, H1 2020
  • Measles - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Measles - Pipeline by Indian Immunologicals Ltd, H1 2020
  • Measles - Pipeline by Micron Biomedical Inc, H1 2020
  • Measles - Pipeline by Panacea Biotec Ltd, H1 2020
  • Measles - Pipeline by Sinovac Biotech Ltd, H1 2020
  • Measles - Pipeline by Univercells SA, H1 2020
  • Measles - Pipeline by VBI Vaccines Inc, H1 2020
  • Measles - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Measles, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Measles - Pipeline Review, H1 2020, provides an overview of the Measles (Infectious Disease) pipeline landscape.

Measles is a highly infectious viral disease. The virus lives in the mucus of the nose and throat of people with this infection. Physical contact, coughing and sneezing can spread the infection. Symptoms of measles are high temperature, sore eyes (conjunctivitis), and a runny nose usually occur first, small white spots usually develop inside the mouth a day or so later, diarrhea and vomiting.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Measles - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Measles (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Measles (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Measles and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 2 and 1 molecules, respectively.

Measles (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Measles (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Measles (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Measles (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Measles (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Measles (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Measles (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Measles (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Measles - Overview
    • Measles - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Measles - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Measles - Companies Involved in Therapeutics Development
    • Biological E Ltd
    • Cadila Healthcare Ltd
    • Daiichi Sankyo Co Ltd
    • Enesi Pharma Ltd
    • GlaxoSmithKline Plc
    • Indian Immunologicals Ltd
    • Micron Biomedical Inc
    • Panacea Biotec Ltd
    • Sinovac Biotech Ltd
    • Univercells SA
    • VBI Vaccines Inc
  • Measles - Drug Profiles
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Edmonston-Zagreb] + mumps [strain Hosino] + rubella [strain RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ERDRP-0519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Measles - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q